"MindMed doses first subject in trial of tablets for generalised anxiety disorder" was originally created and published by ...

Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...

Mind Medicine Inc., a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health ...

MindMed Inc. has announced the dosing of the first patient in its phase 3 Voyage study of MM120 ODT, a pharmaceutically ...

Charles Schwab Investment Management Inc. grew its holdings in shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free ...

Mind Medicine (MNMD) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...

(New York Times) A small randomized trial in China showed that transcutaneous auricular vagus nerve stimulation improved ...

For the first time ever, researchers are administering LSD to patients in a Phase 3 clinical trial. The new study focuses on whether the psychedelic can be used to effectively treat generalized ...

In another inflection point for the psychedelic medicines category, Mind Medicine (MindMed) has claimed breakthrough status from the FDA for its LSD-based candidate MM120 as a treatment for anxiety.